Delaware
|
|
001-12465
|
|
20-0077155
|
(State
or other jurisdiction
of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR
240.13e-4(c))
|
Item 5.03
|
Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal
Year
|
Item 9.01
|
Financial
Statements and
Exhibits
|
(d)
|
Exhibits
|
Exhibit
No.
|
Exhibit
|
3.1
|
Second
Amended and Restated By-Laws of the
Registrant
|
CLEVELAND
BIOLABS, INC.
|
||
|
|
|
Date:
December 5, 2007
|
By: |
/s/
Michael Fonstein
|
Michael
Fonstein
|
||
President
and Chief Executive
Officer
|
Exhibit
No.
|
Exhibit
|
3.1
|
Second
Amended and Restated By-Laws of the
Registrant
|